Report Description of the US Anti-Fungal Market Analysis

Research Scope and Assumption

• The report provides the market value for the base year 2020 and a yearly forecast up to 2028 in terms of revenue (USD billion)


• The key industry dynamics, regulatory scenario, reimbursement scenario, major market trends, and drug markets are evaluated to understand their impacts on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis


• We have used the combination of top-down and bottom-up approach for market sizing, analyzing key regional markets, dynamics, and trends for various solutions, services, and end uses


• All market estimates and forecasts have been validated through primary interviews with the Key Industry Players (KIPs) and secondary analysis


• Inflation has not been accounted for in order to estimate and forecast the market


• Numbers may not add up due to rounding off

Reason to buy the report:

• Facilitate decision-making based on strong current and forecast data for US Anti-Fungal Market Analysis


• Develop strategies based on the latest regulatory framework


• Strategically analyze micro-markets with respect to individual growth trends, future prospects, and their contribution to the market


• Analyze competitive developments such as expansions, investments, mergers & acquisitions, new product developments, and research & developments in the US Anti-Fungal Market Analysis


• Analyze the opportunities in the market for stakeholders and draw a competitive landscape for market leaders


• To strategically profile key players and comprehensively analyze their market shares and core competencies


• We have technically sound team which do a deep dive research and also provide strategy based consulting analysis

US Anti-Fungal Market Analysis Executive Summary

Antifungal drugs are commonly used to cure fungal infections due to unclean, unhygienic, and damp environments. Invasion of epithelial tissue by microscopic organisms leads to fungal infections. Systemic fungal infections are caused due to indigestion or inhalation of spores, leading to fungal pneumonia, and diseases like candidiasis, meningitis, mucormycosis, etc., are caused by opportunistic fungus. Although the majority of fungal infections and diseases are commonly non-lethal, they are very uncomfortable to the host, and their common occurrence is responsible for the rising antifungal drugs market. Antifungal drugs work via various mechanisms such as inhibiting cell wall formation, cell membrane disruption, and cell division.

Market Size and Key Findings

The US Anti-Fungal Market Analysis size stood at around USD 5.15 billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of 3.7% during the forecast period.

The Antifungal Drugs Market size in North America is estimated at USD 5.15 billion in 2020. It is further projected to be growing at a CAGR of 3.7% and worth USD xx billion by 2028. In the following years, the market is poised to grow significantly with the rising global population.



Market Dynamics

Market Growth Drivers Analysis

The North American Antifungal drugs market is expected to be driven by the proliferation of contagious diseases, the rising number of fungal infectious diseases such as miconazole and terbinafine. Also, the increased health concerns and expanding government and non-government support for antifungal disorders are expected to drive the market growth rate throughout the forecast period. The adoption of technological advancement in the production of various pharmaceuticals and delivering effective treatment techniques for various infectious diseases around the region is expected to fuel the growth of North America antifungal drugs market. The market is also likely to be aided by increased investment in research & development institutes. Increased cancer rates, a surge in hematopoietic stem cell transplantation, and other immune system-related factors are all driving the growth of the North American antifungal drugs market.

Market Restraints

The concerned associated long-term side effects with the usage of these drugs hamper the market growth in addition antifungal drug demand is also being slowed by variations in the rate of pharmaceutical manufacture. In addition, the scarcity of qualified personnel in the pharmaceutical manufacturing industries, which is the key restraint in the North America antifungal drugs market. However, the economy slows down, with the pandemic being the primary cause of improper government funds to cure these fungal viral infections. Furthermore, the government's stringent rules and regulations for approving new drugs are the major challenging factor.

COVID-19 impact on US Anti-Fungal Market

The COVID-19 pandemic is expected to have a significant impact on the market. As the import and export activities have been restricted due to the lockdown, it is expected to negatively impact the market studied due to shortage and irregular supply of raw materials and finished medical supplies and drugs. However, this might allow local manufacturers to increase their presence in the market. Supply disruption and medicine shortages of medical supplies have been observed in several countries due to the temporary lockdowns of manufacturing sites, export bans, increased demands for medicine for the treatment of COVID-19, and the stockpiling of medicines by individuals.

Competitive Landscape

Key Players

the key players operating in the antifungal drugs market, such as Pfizer Inc., Sanofi S.A., Gilead Sciences, Inc., Merck & Co., Inc., Novartis International AG, Abbott Laboratories, Bayer AG, Scynexis Inc., Enzon Pharmaceuticals, Inc., and GlaxoSmithKline Plc.

The other players of the antifungals drugs market include Astellas Pharma, Inc., Sigma-Aldrich Corporation, Agilent Technologies, Inc., Beckman Coulter, Inc. (a subsidiary of Danaher Corporation), Kramer Laboratories, Basilea Pharmaceutical Ltd., Valeant Pharmaceuticals International, Inc., and Tecan Group.

Products in Pipeline

• In 2019, Mayne Pharma announced the launch of TOLSURA (SUBA-itraconazole) 65mg capsule in the United States.


• Ibrexafungerp (MK-3118 and SCY-078; developed by Scynexis, Jersey City, NJ, USA) is a first-in-class oral glucan synthase inhibitor.

Notable Recent Deals

In June 2021, Cadila Pharmaceuticals launched a new triazole antifungal drug Posaconazole that is effective against a wide range of invasive fungal diseases. Additionally, the drug has been recommended as a second-line treatment for Mucormycosis.

In June 2021, Scynexis announced the approval of Brexafemme, bu the United States Food and Drug Administration for the treatment of vaginal yeast infections.

Healthcare Policies and Regulatory Landscape

Policy changes and Reimbursement scenario

Private plans typically include medical and pharmacy benefits. Drugs used with Durable Medical Equipment (DME) are often covered under the pharmacy benefit. Physician-administered drugs, regardless of formulation, are typically covered and paid under the medical benefit. FDA approval is typically a prerequisite for coverage, but private plans have a greater flexibility than public plans in defining the benefit category and placement of drugs on formularies, as well as adopting utilization controls.